29 completed, 10 recruiting, 10 unknown, 8 terminated. 70 Phase 2, 17 Phase 1, 6 Phase 3.
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy Allogeneic Stem Cell Transplant - MDS, Myelodysplastic Syndrome MDS | Phase 2 | Not yet recruiting | Ronald Paquette | 20 | 2026-12-01 | 2026-10-28 |
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped mBUCY, mBUCY conditioning Regimen Group - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 180 | 2026-06-01 | 2026-06-10 |
| SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 160 | 2026-06-01 | 2026-05-01 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| Reduced Intensity Conditioning for MDS Fludarabine; melphalan; busulfan - MDS | Phase 2 | Not yet recruiting | Ruijin Hospital | 45 | 2025-08-01 | 2025-07-25 |
| Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation Ivosidenib 250 MG (milligram) - AML, MDS | Phase 2 | Recruiting | Technische Universität Dresden | 76 | 2025-06-17 | 2026-08-26 |
| Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation Decitabine, Sorafenib (BAY-43-9006)，giritinib, Avastinib - AML, MDS | Phase 2 / Phase 3 | Recruiting | Ruijin Hospital | 126 | 2025-06-10 | 2025-05-18 |
| Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG) - Leukemia, MDS | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 24 | 2025-05-03 | 2026-08-05 |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT selinexor in combination with venetoclax - MDS, AML, Adult | Phase 2 | Not yet recruiting | Ruijin Hospital | 73 | 2025-01-01 | 2025-01-09 |
| A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor Azacitidine or Ruxolitinib combined with Selinexor - MDS | Phase 2 | Enrolling by invitation | Peking Union Medical College Hospital | 39 | 2024-11-06 | 2024-10-30 |
| A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes HS-20106 - Myelodysplastic Syndromes, Anemia | Phase 2 | Not yet recruiting | Hansoh BioMedical R&D Company | 176 | 2024-10-30 | 2024-09-19 |
| Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML Decitabine, Venetoclax - AML, MDS | Phase 2 | Recruiting | University Hospital Tuebingen | 27 | 2023-11-04 | 2025-04-08 |
| A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies Decitabine, Filgrastim - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Active not recruiting | Franziska Wachter | 29 | 2023-04-19 | 2026-08-20 |
| Venetoclax in Patients With MDS or AML in Relapse After AHSCT venetoclax + azacitidine +/- donor lymphocyte infusion - MDS, AML | Phase 1 / Phase 2 | Active not recruiting | Groupe Francophone des Myelodysplasies | 55 | 2022-11-23 | 2026-03-12 |
| Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies Venetoclax plus RIC - Leukemia, Myeloid, Acute, MDS | Phase 2 | Unknown | Xianmin Song, MD | 50 | 2022-11-01 | 2023-11-28 |
| Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA Luspatercept Injection [Reblozyl], Eprex - MDS, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Groupe Francophone des Myelodysplasies | 150 | 2022-05-18 | 2026-09-29 |
| A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure Vibecotamab, Dexamethasone, Acetaminophen - AML, MDS | Phase 2 | Terminated | M.D. Anderson Cancer Center | 51 | 2022-05-06 | 2026-05-22 |
| Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) Fedratinib Pill - Myeloproliferative Neoplasm, Chronic Neutrophilic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2022-03-01 | 2026-06-09 |
Showing 20 of 70. Sign in to see all of them.
Myelodysplastic Syndromes (20) · Leukemia, Myeloid, Acute (18) · Leukemia (8) · Lymphoma (6) · Anemia, Refractory, with Excess of Blasts (5) · Hematologic Neoplasms (5) · Myeloproliferative Disorders (5) · Leukemia, Myelomonocytic, Chronic (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Blast Crisis (3) · Multiple Myeloma (3) · Thrombocytopenia (3) · Bone Marrow Diseases (2) · Cytopenia (2) · Hematologic Diseases (2)
Hemic and Lymphatic Diseases (43) · Hematologic Diseases (40) · Neoplasms by Histologic Type (27) · Neoplasms (26) · Bone Marrow Diseases (25) · Leukemia, Myeloid (19) · Leukemia (18) · Immune System Diseases (14) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Disease Attributes (9) · Chronic Disease (7)
Azacitidine (15) · Cyclophosphamide (10) · fludarabine (9) · Busulfan (7) · Decitabine (7) · Granulocyte Colony-Stimulating Factor (6) · Mycophenolic Acid (6) · Whole-Body Irradiation (6) · fludarabine phosphate (6) · Lenalidomide (5) · venetoclax (5) · Antilymphocyte Serum (4) · Cyclosporine (4) · Cytarabine (4) · Clofarabine (3)
Groupe Francophone des Myelodysplasies (6) · Amgen (3) · Masonic Cancer Center, University of Minnesota (3) · Ruijin Hospital (3) · The First Affiliated Hospital of Soochow University (3) · Astex Pharmaceuticals, Inc. (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Peking Union Medical College Hospital (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Ascentage Pharma Group Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Beth Israel Deaconess Medical Center (1) · BioSight Ltd. (1)
United States (32) · China (13) · France (8) · Germany (5) · Canada (3) · Italy (3) · Belgium (2) · Norway (2) · South Korea (2) · Austria (1) · Denmark (1) · Hong Kong (1) · Japan (1) · Sweden (1)
Gautam Borthakur, MD (2) · Guillermo Garcia-Manero, MD (2) · Anders Erik Astrup Dahm, MD, PHD (1) · Andrew Kuykendall, MD (1) · Arnold Ganser, Prof. Dr. (1) · Bing Han, Docter (1) · Chetan Jeurkar, DO (1) · Claudia Lengerke, Prof. (1) · Claudio G. Brunstein, MD, PhD (1) · Danielle E Pregent-Arnold, M.D. (1) · David E Avigan, MD (1) · David F McDermott, MD (1) · Dennis D Hickstein, M.D. (1)
PMID 18997171, PMID 19706886, PMID 21508125, PMID 21719884, PMID 21816832, PMID 23344397, PMID 24077845, PMID 24951467, PMID 26296954, PMID 27250349, PMID 28881839, PMID 30926081, PMID 31060979, PMID 31331399, PMID 32264726, PMID 32285126, PMID 32556286, PMID 32813874, PMID 34106753, PMID 36251401, PMID 36737440, PMID 37595058, PMID 37607457, PMID 38114624, PMID 38261970, PMID 40784355, PMID 42365365
2015 (1), 2016 (1), KL2RR025006 (1), P30CA033572 (1), U10HL069294 (1), U24CA076518 (1)